暗記メーカー

暗記メーカー

​
ログイン
Module 3 Rationales
100問 • 1年前
  • ユーザ名非公開
    • 通報

    問題一覧

  • 1

    Partial Agonist • Buspirone

    5-HT1A

  • 2

    Serotonin Partial Agonists • Sumatriptan • Naratriptan • Zolmitriptan

    5-HT1B/1D

  • 3

    Full Agonists • Ergotamine • Ergonovine • DHEA

    5-HT2A

  • 4

    Full Agonist • Lorcaserin

    5-HT2C

  • 5

    Partial Agonists • Tegaserod • Cisapride • Full Agonist • Prucalopride

    5-HT4

  • 6

    • Ketanserin • Ritanserin

    5-HT2

  • 7

    Ondansetron • Granisetron • Ramasetron • Palonosetron

    5-HT3

  • 8

    Anxiety, depression

    Buspirone

  • 9

    Migraine, cluster headache

    Sumatriptan / Naratriptan /Zolmitriptan

  • 10

    Obesity

    Lorcaserin

  • 11

    Hypertension

    Ketanserin / Ritanserin

  • 12

    Chemo-induced nausea and vomiting

    Ondansetron / Granisetron /Ramasetron / Palonosetron

  • 13

    *Incomplete solution *Precipitation *Liquefaction

    PHYSICAL INCOMPATIBILITIES

  • 14

    *Polymorphism *Sorption *Volatilization *Loss of water

    PHYSICAL INCOMPATIBILITIES

  • 15

    *Redox *Hydrolysis *Acid-base reaction *Racemization

    CHEMICAL INCOMPATIBILITIES

  • 16

    *Optical isomerism *Solvolysis *Explosive mixture

    CHEMICAL INCOMPATIBILITIES

  • 17

    *Photooxidative degradation *Gelatinization *Cementation

    CHEMICAL INCOMPATIBILITIES

  • 18

    1 + 1 = 2

    ADDITIVE

  • 19

    Sum of the effects of each drug used individually is higher than the effect of drug alone

    ADDITIVE

  • 20

    1 + 1 = 3

    SYNERGISTIC

  • 21

    Enhanced efficacy of the combination

    SYNERGISTIC

  • 22

    1 + 0 = 2 or 1 + 0 > 2

    POTENTIATION

  • 23

    One drug has no effect on its own but increases the effect of the other

    POTENTIATION

  • 24

    1 + 1 = 0

    ANTAGONISTIC (Non-beneficial)

  • 25

    Effect of one drug is decreased or suppressed by another drug

    ANTAGONISTIC (Non-beneficial)

  • 26

    Psidium guajava

    Bayabas

  • 27

    Astringent

    Bayabas

  • 28

    Momordica charantia

    Ampalaya

  • 29

    Antidiabetic

    Ampalaya

  • 30

    Allium sativum

    Bawang

  • 31

    Anti-dyslipidemia

    Bawang

  • 32

    Cinopodium douglasii

    Yerba Buena

  • 33

    Analgesic

    Yerba Buena

  • 34

    Peperomia pellucida

    Pansit-pansitan

  • 35

    Antigout

    Pansit-pansitan

  • 36

    Vitex negundo

    Lagundi

  • 37

    Cough

    Lagundi

  • 38

    Cassia alata

    Akapulko

  • 39

    Antifungal

    Cassia alata

  • 40

    Quisqualis indica L.

    Niyog-niyogan

  • 41

    Anthelmintic

    Niyog-niyogan

  • 42

    Situation in which the pharmacologic effects of one drug are altered by prior or concurrent administration of another substance

    Drug Interaction

  • 43

    Affected by the interaction

    Object Drug

  • 44

    Caused the interaction

    Precipitant Drug

  • 45

    Barbiturates (Thiopental) Dissociative (Ketamine)

    Opioid IV

  • 46

    Opioids (Fentanyl) Benzodiazepines (Midazolam)

    Opioid IV

  • 47

    Miscellaneous (Etomidate, Propofol)

    Opioid IV

  • 48

    Gas (Nitrous Oxide) Volatile Liquids (Halothane)

    Opioid Inhaled

  • 49

    HMG-CoA REDUCTASE INHIBITORS S/E Monitor serum transaminase levels

    Liver

  • 50

    HMG-CoA REDUCTASE INHIBITORS S/E Myopathy, rhabdomyolysis

    Muscle

  • 51

    HMG-CoA REDUCTASE INHIBITORS S/E Monitor plasma creatine kinase levels

    Muscle

  • 52

    HMG-CoA REDUCTASE INHIBITORS S/E Contraindicated during pregnancy and in nursing mothers

    Teratogenic

  • 53

    (Extra Pyrymidal Syndrome Manifestations) Uncontrolled restlessness Most difficult to treat

    Akathisia

  • 54

    (Extra Pyrymidal Syndrome Manifestations) Only EPS that is NOT treated with anticholinergics

    Akathisia

  • 55

    Treatment for Akathisia

    BZD / Propranolol

  • 56

    (Extra Pyrymidal Syndrome Manifestations) Aka Retrocollis, Torticollis, Twisting of neck

    Dystonia

  • 57

    (Extra Pyrymidal Syndrome Manifestations) *1st EPS seen *Easier to treat but can be fatal

    Dystonia

  • 58

    Treatment for Dystonia

    IV Diphenhydramine / CNS Anticholinergics

  • 59

    Treatment for Extra Pyrymidal Syndrome

    BZD / Propranolol

  • 60

    Warfarin (anticoagulant) + Ginseng (anticoagulant)

    additive

  • 61

    Provides the most current information Ex. Journal Articles

    Primary Literature

  • 62

    For selective and quick screening or primary literature Ex. Abstracting and Indexing Services

    Secondary Literature

  • 63

    For easy and convenient access *Info may be outdated Ex. Textbooks

    Tertiary Literature

  • 64

    <0.9% NaCl

    Hypotonic

  • 65

    0.9% NaCl

    Isotonic

  • 66

    > 0.9% NaCl

    Hypertonic

  • 67

    Removal of cholesterol from tissues outside the liver

    High Density Lipoprotein (HDL)

  • 68

    Endogenous cholesterol transport

    Low Density Lipoprotein (LDL)

  • 69

    Endogenous cholesterol transport, triglyceride transport

    Low Density Lipoprotein (LDL)

  • 70

    Endogenous triglyceride transport

    Low Density Lipoprotein (LDL)

  • 71

    Study of genetic variations that influence individuals’ responses to drugs, examines polymorphisms that code for drug transporters, drug-metabolizing enzymes and drug receptors

    Pharmacogenetic

  • 72

    Genome-wide analysis of genetic determinants of drug efficacy and toxicity

    Pharmacogenomics

  • 73

    Valproic Acid

    ENZYME INHIBITORS

  • 74

    Grapefruit Juice

    ENZYME INHIBITORS

  • 75

    Omeprazole

    ENZYME INHIBITORS

  • 76

    Acute Alcoholism

    ENZYME INHIBITORS

  • 77

    Ritonavir

    ENZYME INHIBITORS

  • 78

    Ketoconazole

    ENZYME INHIBITORS

  • 79

    Macrolide (except Azithromycin)

    ENZYME INHIBITORS

  • 80

    Cimetidine

    ENZYME INHIBITORS

  • 81

    Isoniazid

    ENZYME INHIBITORS

  • 82

    Metronidazole

    ENZYME INHIBITORS

  • 83

    Disulfiram

    ENZYME INHIBITORS

  • 84

    Amiodarone

    ENZYME INHIBITORS

  • 85

    Amiodarone

    ENZYME INHIBITORS

  • 86

    Phenytoin

    ENZYME INDUCERS

  • 87

    Phenobarbital

    ENZYME INDUCERS

  • 88

    Rifampicin

    ENZYME INDUCERS

  • 89

    Carbamazepine

    ENZYME INDUCERS

  • 90

    Chronic alcoholism

    ENZYME INDUCERS

  • 91

    Smoking

    ENZYME INDUCERS

  • 92

    St. John’s Wort

    ENZYME INDUCERS

  • 93

    Increase enzyme = Increase Metabolism = Decrease Object Drug

    ENZYME INDUCERS

  • 94

    Decrease enzyme = Decrease Metabolism = Increase Object Drug

    ENZYME INHIBITORS

  • 95

    Statement regarding the conditions wherein the use of the drug product may cause harm to the patient

    Contraindication

  • 96

    Istruction and the special care required in the use of the drug product to avoid undesired effects and to ensure its safe and effective use

    Precaution

  • 97

    Statements regarding the occurrence of potential hazards and undesirable effects associated with the use of the drug product and the limitation of its use

    Warning

  • 98

    CCBs

    -dipines

  • 99

    H2 blocker

    -tidines

  • 100

    ACEi

    -prils

    • Module 2 Part 1

    Module 2 Part 1

    ユーザ名非公開 · 100問 · 1年前

    Module 2 Part 1

    Module 2 Part 1

    100問 • 1年前
    ユーザ名非公開

    Module 1

    Module 1

    ユーザ名非公開 · 13問 · 1年前

    Module 1

    Module 1

    13問 • 1年前
    ユーザ名非公開

    Module 2

    Module 2

    ユーザ名非公開 · 100問 · 1年前

    Module 2

    Module 2

    100問 • 1年前
    ユーザ名非公開

    Antibiotics

    Antibiotics

    ユーザ名非公開 · 10問 · 1年前

    Antibiotics

    Antibiotics

    10問 • 1年前
    ユーザ名非公開

    Module 2 Part 2

    Module 2 Part 2

    ユーザ名非公開 · 100問 · 1年前

    Module 2 Part 2

    Module 2 Part 2

    100問 • 1年前
    ユーザ名非公開

    Module 2 (Part 2)

    Module 2 (Part 2)

    ユーザ名非公開 · 100問 · 1年前

    Module 2 (Part 2)

    Module 2 (Part 2)

    100問 • 1年前
    ユーザ名非公開

    Module 2 Part 3

    Module 2 Part 3

    ユーザ名非公開 · 85問 · 1年前

    Module 2 Part 3

    Module 2 Part 3

    85問 • 1年前
    ユーザ名非公開

    Module 4

    Module 4

    ユーザ名非公開 · 100問 · 1年前

    Module 4

    Module 4

    100問 • 1年前
    ユーザ名非公開

    Module 4 Part 2

    Module 4 Part 2

    ユーザ名非公開 · 100問 · 1年前

    Module 4 Part 2

    Module 4 Part 2

    100問 • 1年前
    ユーザ名非公開

    Module 4 Part 3

    Module 4 Part 3

    ユーザ名非公開 · 60問 · 1年前

    Module 4 Part 3

    Module 4 Part 3

    60問 • 1年前
    ユーザ名非公開

    Module 2 (Part 4)

    Module 2 (Part 4)

    ユーザ名非公開 · 68問 · 1年前

    Module 2 (Part 4)

    Module 2 (Part 4)

    68問 • 1年前
    ユーザ名非公開

    Randome Questions

    Randome Questions

    ユーザ名非公開 · 13問 · 1年前

    Randome Questions

    Randome Questions

    13問 • 1年前
    ユーザ名非公開

    1

    1

    ユーザ名非公開 · 100問 · 1年前

    1

    1

    100問 • 1年前
    ユーザ名非公開

    Module 2 (Part 5)

    Module 2 (Part 5)

    ユーザ名非公開 · 100問 · 1年前

    Module 2 (Part 5)

    Module 2 (Part 5)

    100問 • 1年前
    ユーザ名非公開

    2

    2

    ユーザ名非公開 · 100問 · 1年前

    2

    2

    100問 • 1年前
    ユーザ名非公開

    Module 2 (Part 6)

    Module 2 (Part 6)

    ユーザ名非公開 · 68問 · 1年前

    Module 2 (Part 6)

    Module 2 (Part 6)

    68問 • 1年前
    ユーザ名非公開

    Module 4 Part 1

    Module 4 Part 1

    ユーザ名非公開 · 5問 · 1年前

    Module 4 Part 1

    Module 4 Part 1

    5問 • 1年前
    ユーザ名非公開

    問題一覧

  • 1

    Partial Agonist • Buspirone

    5-HT1A

  • 2

    Serotonin Partial Agonists • Sumatriptan • Naratriptan • Zolmitriptan

    5-HT1B/1D

  • 3

    Full Agonists • Ergotamine • Ergonovine • DHEA

    5-HT2A

  • 4

    Full Agonist • Lorcaserin

    5-HT2C

  • 5

    Partial Agonists • Tegaserod • Cisapride • Full Agonist • Prucalopride

    5-HT4

  • 6

    • Ketanserin • Ritanserin

    5-HT2

  • 7

    Ondansetron • Granisetron • Ramasetron • Palonosetron

    5-HT3

  • 8

    Anxiety, depression

    Buspirone

  • 9

    Migraine, cluster headache

    Sumatriptan / Naratriptan /Zolmitriptan

  • 10

    Obesity

    Lorcaserin

  • 11

    Hypertension

    Ketanserin / Ritanserin

  • 12

    Chemo-induced nausea and vomiting

    Ondansetron / Granisetron /Ramasetron / Palonosetron

  • 13

    *Incomplete solution *Precipitation *Liquefaction

    PHYSICAL INCOMPATIBILITIES

  • 14

    *Polymorphism *Sorption *Volatilization *Loss of water

    PHYSICAL INCOMPATIBILITIES

  • 15

    *Redox *Hydrolysis *Acid-base reaction *Racemization

    CHEMICAL INCOMPATIBILITIES

  • 16

    *Optical isomerism *Solvolysis *Explosive mixture

    CHEMICAL INCOMPATIBILITIES

  • 17

    *Photooxidative degradation *Gelatinization *Cementation

    CHEMICAL INCOMPATIBILITIES

  • 18

    1 + 1 = 2

    ADDITIVE

  • 19

    Sum of the effects of each drug used individually is higher than the effect of drug alone

    ADDITIVE

  • 20

    1 + 1 = 3

    SYNERGISTIC

  • 21

    Enhanced efficacy of the combination

    SYNERGISTIC

  • 22

    1 + 0 = 2 or 1 + 0 > 2

    POTENTIATION

  • 23

    One drug has no effect on its own but increases the effect of the other

    POTENTIATION

  • 24

    1 + 1 = 0

    ANTAGONISTIC (Non-beneficial)

  • 25

    Effect of one drug is decreased or suppressed by another drug

    ANTAGONISTIC (Non-beneficial)

  • 26

    Psidium guajava

    Bayabas

  • 27

    Astringent

    Bayabas

  • 28

    Momordica charantia

    Ampalaya

  • 29

    Antidiabetic

    Ampalaya

  • 30

    Allium sativum

    Bawang

  • 31

    Anti-dyslipidemia

    Bawang

  • 32

    Cinopodium douglasii

    Yerba Buena

  • 33

    Analgesic

    Yerba Buena

  • 34

    Peperomia pellucida

    Pansit-pansitan

  • 35

    Antigout

    Pansit-pansitan

  • 36

    Vitex negundo

    Lagundi

  • 37

    Cough

    Lagundi

  • 38

    Cassia alata

    Akapulko

  • 39

    Antifungal

    Cassia alata

  • 40

    Quisqualis indica L.

    Niyog-niyogan

  • 41

    Anthelmintic

    Niyog-niyogan

  • 42

    Situation in which the pharmacologic effects of one drug are altered by prior or concurrent administration of another substance

    Drug Interaction

  • 43

    Affected by the interaction

    Object Drug

  • 44

    Caused the interaction

    Precipitant Drug

  • 45

    Barbiturates (Thiopental) Dissociative (Ketamine)

    Opioid IV

  • 46

    Opioids (Fentanyl) Benzodiazepines (Midazolam)

    Opioid IV

  • 47

    Miscellaneous (Etomidate, Propofol)

    Opioid IV

  • 48

    Gas (Nitrous Oxide) Volatile Liquids (Halothane)

    Opioid Inhaled

  • 49

    HMG-CoA REDUCTASE INHIBITORS S/E Monitor serum transaminase levels

    Liver

  • 50

    HMG-CoA REDUCTASE INHIBITORS S/E Myopathy, rhabdomyolysis

    Muscle

  • 51

    HMG-CoA REDUCTASE INHIBITORS S/E Monitor plasma creatine kinase levels

    Muscle

  • 52

    HMG-CoA REDUCTASE INHIBITORS S/E Contraindicated during pregnancy and in nursing mothers

    Teratogenic

  • 53

    (Extra Pyrymidal Syndrome Manifestations) Uncontrolled restlessness Most difficult to treat

    Akathisia

  • 54

    (Extra Pyrymidal Syndrome Manifestations) Only EPS that is NOT treated with anticholinergics

    Akathisia

  • 55

    Treatment for Akathisia

    BZD / Propranolol

  • 56

    (Extra Pyrymidal Syndrome Manifestations) Aka Retrocollis, Torticollis, Twisting of neck

    Dystonia

  • 57

    (Extra Pyrymidal Syndrome Manifestations) *1st EPS seen *Easier to treat but can be fatal

    Dystonia

  • 58

    Treatment for Dystonia

    IV Diphenhydramine / CNS Anticholinergics

  • 59

    Treatment for Extra Pyrymidal Syndrome

    BZD / Propranolol

  • 60

    Warfarin (anticoagulant) + Ginseng (anticoagulant)

    additive

  • 61

    Provides the most current information Ex. Journal Articles

    Primary Literature

  • 62

    For selective and quick screening or primary literature Ex. Abstracting and Indexing Services

    Secondary Literature

  • 63

    For easy and convenient access *Info may be outdated Ex. Textbooks

    Tertiary Literature

  • 64

    <0.9% NaCl

    Hypotonic

  • 65

    0.9% NaCl

    Isotonic

  • 66

    > 0.9% NaCl

    Hypertonic

  • 67

    Removal of cholesterol from tissues outside the liver

    High Density Lipoprotein (HDL)

  • 68

    Endogenous cholesterol transport

    Low Density Lipoprotein (LDL)

  • 69

    Endogenous cholesterol transport, triglyceride transport

    Low Density Lipoprotein (LDL)

  • 70

    Endogenous triglyceride transport

    Low Density Lipoprotein (LDL)

  • 71

    Study of genetic variations that influence individuals’ responses to drugs, examines polymorphisms that code for drug transporters, drug-metabolizing enzymes and drug receptors

    Pharmacogenetic

  • 72

    Genome-wide analysis of genetic determinants of drug efficacy and toxicity

    Pharmacogenomics

  • 73

    Valproic Acid

    ENZYME INHIBITORS

  • 74

    Grapefruit Juice

    ENZYME INHIBITORS

  • 75

    Omeprazole

    ENZYME INHIBITORS

  • 76

    Acute Alcoholism

    ENZYME INHIBITORS

  • 77

    Ritonavir

    ENZYME INHIBITORS

  • 78

    Ketoconazole

    ENZYME INHIBITORS

  • 79

    Macrolide (except Azithromycin)

    ENZYME INHIBITORS

  • 80

    Cimetidine

    ENZYME INHIBITORS

  • 81

    Isoniazid

    ENZYME INHIBITORS

  • 82

    Metronidazole

    ENZYME INHIBITORS

  • 83

    Disulfiram

    ENZYME INHIBITORS

  • 84

    Amiodarone

    ENZYME INHIBITORS

  • 85

    Amiodarone

    ENZYME INHIBITORS

  • 86

    Phenytoin

    ENZYME INDUCERS

  • 87

    Phenobarbital

    ENZYME INDUCERS

  • 88

    Rifampicin

    ENZYME INDUCERS

  • 89

    Carbamazepine

    ENZYME INDUCERS

  • 90

    Chronic alcoholism

    ENZYME INDUCERS

  • 91

    Smoking

    ENZYME INDUCERS

  • 92

    St. John’s Wort

    ENZYME INDUCERS

  • 93

    Increase enzyme = Increase Metabolism = Decrease Object Drug

    ENZYME INDUCERS

  • 94

    Decrease enzyme = Decrease Metabolism = Increase Object Drug

    ENZYME INHIBITORS

  • 95

    Statement regarding the conditions wherein the use of the drug product may cause harm to the patient

    Contraindication

  • 96

    Istruction and the special care required in the use of the drug product to avoid undesired effects and to ensure its safe and effective use

    Precaution

  • 97

    Statements regarding the occurrence of potential hazards and undesirable effects associated with the use of the drug product and the limitation of its use

    Warning

  • 98

    CCBs

    -dipines

  • 99

    H2 blocker

    -tidines

  • 100

    ACEi

    -prils